Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$17.44

(0.00%)

04:55
06/14/18
06/14
04:55
06/14/18
04:55

Horizon Pharma management to meet with Jefferies

Meetings to be held in Kansas City, MO on June 13 and in Denver on June 14 hosted by Jefferies.

  • 14

    Jun

HZNP Horizon Pharma
$17.44

(0.00%)

03/01/18
UBSW
03/01/18
NO CHANGE
Target $20
UBSW
Buy
Horizon Pharma one of best profiles in specialty pharma, says UBS
UBS analyst Marc Goodman said Horizon Pharma has one of the best profiles in specialty pharma given its high single-digit to low double-digit sales growth to drive at least low double-digit EBITDA through 2022. Goodman reiterated his Buy rating and $20 price target on Horizon Pharma shares.
03/15/18
CANT
03/15/18
NO CHANGE
Target $17
CANT
Overweight
Physicians divided on adoption of Horizon's Krystexxa, says Cantor Fitzgerald
Since Horizon Pharma guided to a 50% year-over-year increase in Krystexxa sales in 2018 and peak sales of $750M, there has been "considerable debate as to whether or not the company can meet these high expectations," Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After hosting calls with four rheumatologists that treat a large number of gout patients, the analyst says that while physicians believe Krystexxa is the safest and most-efficacious gout drug, they were not all convinced they would switch their patients over to Krystexxa. Chen sees division over Krystexxa adoption but keeps an Overweight rating on Horizon Pharma with a $17 price target.
04/11/18
MZHO
04/11/18
NO CHANGE
Target $18
MZHO
Buy
Selecta drug not imminent threat to Horizon Pharma, says Mizuho
Mizuho analyst Irina Koffler says competitor Selecta Biosciences (SELB) released "directionally positive," but early, data on a potential competitive product to Horizon Pharma's key orphan drug Krystexxa. The analyst does not view Selecta's SEL-212 as an imminent threat to Horizon. She reiterates a Buy rating on Horizon with an $18 price target.
04/16/18
CANT
04/16/18
NO CHANGE
Target $17
CANT
Overweight
Cantor positive on Horizon Pharma after speaking to rheumatologists
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Horizon Pharma with a $17 price target after holding a conference call with two rheumatologists to discuss the market opportunity for Krystexxa. Both doctors agreed that Krystexxa is a very good drug and works best for a small group of refractory patients, which is all Horizon needs to meet or beat its peak sales forecast, Chen tells investors in a research note. The analyst believes there has been considerable debate as to whether the company can meet its forecasts.

TODAY'S FREE FLY STORIES

PETQ

PetIQ

$41.01

-0.61 (-1.47%)

16:04
09/24/18
09/24
16:04
09/24/18
16:04
Syndicate
PetIQ announces offering of common stock »

PetIQ announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$280.92

0.1 (0.04%)

16:04
09/24/18
09/24
16:04
09/24/18
16:04
Hot Stocks
Ulta Beauty's Charles Philippin to resign as non-executive board chairperson »

Ulta Beauty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTI

Pluristem

$1.32

0.01 (0.76%)

16:04
09/24/18
09/24
16:04
09/24/18
16:04
Hot Stocks
Pluristem treatment of graft failure granted FDA orphan designation »

Pluristem's ex-vivo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBL

GAMCO Investors

$24.55

-0.24 (-0.97%)

, XRM

Xerium Technologies

$13.41

0.015 (0.11%)

16:03
09/24/18
09/24
16:03
09/24/18
16:03
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Xerium Technologies »

Gabelli reports 6.13%…

GBL

GAMCO Investors

$24.55

-0.24 (-0.97%)

XRM

Xerium Technologies

$13.41

0.015 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$2.62

-0.05 (-1.87%)

16:03
09/24/18
09/24
16:03
09/24/18
16:03
Hot Stocks
Cellectar granted orphan status for osteosarcoma treatment »

The FDA granted Cellectar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.27

-0.035 (-0.56%)

16:03
09/24/18
09/24
16:03
09/24/18
16:03
Hot Stocks
New York Mortgage promotes Nathan Reese to COO »

New York Mortgage Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPNT

Opiant Pharmaceuticals

$21.00

-1.01 (-4.59%)

16:03
09/24/18
09/24
16:03
09/24/18
16:03
Syndicate
Opiant Pharmaceuticals announces common stock offering »

Opiant Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ARNA

Arena Pharmaceuticals

$42.90

-0.95 (-2.17%)

16:02
09/24/18
09/24
16:02
09/24/18
16:02
Hot Stocks
Arena Pharmaceuticals reports 'positive' Phase 2a results for olorinab »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

ANAB

AnaptysBio

$104.08

11.25 (12.12%)

16:02
09/24/18
09/24
16:02
09/24/18
16:02
Syndicate
AnaptysBio announces $200M common stock offering »

AnaptysBio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

16:00
09/24/18
09/24
16:00
09/24/18
16:00
General news
U.S. Consumer Confidence Preview: »

U.S. Consumer Confidence…

BIOC

Biocept

$2.91

-0.08 (-2.68%)

15:58
09/24/18
09/24
15:58
09/24/18
15:58
Hot Stocks
Breaking Hot Stocks news story on Biocept »

Lincoln Park Capital Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$16.34

-5.03 (-23.54%)

15:55
09/24/18
09/24
15:55
09/24/18
15:55
Conference/Events
Spectrum to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

ASPS

Altisource

$34.40

0.3 (0.88%)

15:55
09/24/18
09/24
15:55
09/24/18
15:55
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VSTM

Verastem

$8.89

0.22 (2.54%)

15:51
09/24/18
09/24
15:51
09/24/18
15:51
Hot Stocks
Verastem receives FDA approval of Copiktra capsules »

Verastem announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

JBL

Jabil

$30.11

0.25 (0.84%)

15:50
09/24/18
09/24
15:50
09/24/18
15:50
Options
Jabil options volume is 12X daily average ahead of earnings »

Jabil options volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

TDOC

Teladoc

$78.35

0.25 (0.32%)

15:42
09/24/18
09/24
15:42
09/24/18
15:42
Conference/Events
Teladoc to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

CWH

Camping World

$20.48

-1.59 (-7.20%)

15:40
09/24/18
09/24
15:40
09/24/18
15:40
Options
Closing call option block in Camping World as shares retreat »

Closing call option block…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

SEAS

SeaWorld

$29.91

-0.19 (-0.63%)

15:35
09/24/18
09/24
15:35
09/24/18
15:35
Options
SeaWorld put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$95.05

-0.8 (-0.83%)

, IBM

IBM

$149.98

-1.31 (-0.87%)

15:31
09/24/18
09/24
15:31
09/24/18
15:31
Periodicals
Walmart requires lettuce, spinach suppliers to join blockchain, WSJ reports »

In a letter to suppliers,…

WMT

Walmart

$95.05

-0.8 (-0.83%)

IBM

IBM

$149.98

-1.31 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 22

    Oct

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

FL

Foot Locker

$47.57

-0.71 (-1.47%)

15:25
09/24/18
09/24
15:25
09/24/18
15:25
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

CDNA

CareDx

$26.73

0.75 (2.89%)

, NTRA

Natera

$23.95

-0.23 (-0.95%)

15:25
09/24/18
09/24
15:25
09/24/18
15:25
Conference/Events
Piper Jaffray biotech analysts to hold an analyst/industry conference call »

Biotech Analysts discuss…

CDNA

CareDx

$26.73

0.75 (2.89%)

NTRA

Natera

$23.95

-0.23 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 01

    Oct

  • 15

    Nov

  • 27

    Nov

SBUX

Starbucks

$56.91

-0.49 (-0.85%)

15:24
09/24/18
09/24
15:24
09/24/18
15:24
Periodicals
Starbucks plans 'significant changes' to company structure, Bloomberg says »

Starbucks is planning an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TMK

Torchmark

$88.45

-0.51 (-0.57%)

15:17
09/24/18
09/24
15:17
09/24/18
15:17
Syndicate
Breaking Syndicate news story on Torchmark »

Torchmark files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/24/18
09/24
15:17
09/24/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/24/18
09/24
15:16
09/24/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.